Epstein–Barr Virus Nuclear Antigen 3C Binds to BATF/IRF4 or SPI1/IRF4 Composite Sites and Recruits Sin3A to Repress CDKN2A
Sizun Jiang,Bradford Willox,Hufeng Zhou,Amy M. Holthaus,Anqi Wang,T. T. Shi,S. Maruo,P. Kharchenko,E. Johannsen,E. Kieff,Bo Zhao
DOI: https://doi.org/10.1073/pnas.1321704111
2013-01-01
Abstract:Significance Epstein–Barr virus (EBV) is an important causative agent of B-cell lymphomas and Hodgkin disease in immune-deficient people, including HIV-infected people. The experiments described here were undertaken to determine the mechanisms through which the EBV-encoded nuclear protein EBNA3C blocks the cell p14ARF and p16INK4A tumor suppressor-mediated inhibition of EBV-infected B-cell growth, thereby unfettering EBV-driven B-cell proliferation. The experiments also identify the molecular basis for diverse EBNA3C enhancer interactions with cell DNA-binding proteins and cell DNA to regulate MYC, pRB, BCL2, and BIM expression. Surprisingly, EBNA3C’s role in enhancer-mediated cell gene transcription up-regulation is primarily mediated by combinatorial effects with cell transcription factors, most notably AICEs, EICEs, and RUNX3. Epstein–Barr virus nuclear antigen 3C (EBNA3C) repression of CDKN2A p14ARF and p16INK4A is essential for immortal human B-lymphoblastoid cell line (LCL) growth. EBNA3C ChIP-sequencing identified >13,000 EBNA3C sites in LCL DNA. Most EBNA3C sites were associated with active transcription; 64% were strong H3K4me1- and H3K27ac-marked enhancers and 16% were active promoters marked by H3K4me3 and H3K9ac. Using ENCODE LCL transcription factor ChIP-sequencing data, EBNA3C sites coincided (±250 bp) with RUNX3 (64%), BATF (55%), ATF2 (51%), IRF4 (41%), MEF2A (35%), PAX5 (34%), SPI1 (29%), BCL11a (28%), SP1 (26%), TCF12 (23%), NF-κB (23%), POU2F2 (23%), and RBPJ (16%). EBNA3C sites separated into five distinct clusters: (i) Sin3A, (ii) EBNA2/RBPJ, (iii) SPI1, and (iv) strong or (v) weak BATF/IRF4. EBNA3C signals were positively affected by RUNX3, BATF/IRF4 (AICE) and SPI1/IRF4 (EICE) cooccupancy. Gene set enrichment analyses correlated EBNA3C/Sin3A promoter sites with transcription down-regulation (P < 1.6 × 10−4). EBNA3C signals were strongest at BATF/IRF4 and SPI1/IRF4 composite sites. EBNA3C bound strongly to the p14ARF promoter through SPI1/IRF4/BATF/RUNX3, establishing RBPJ-, Sin3A-, and REST-mediated repression. EBNA3C immune precipitated with Sin3A and conditional EBNA3C inactivation significantly decreased Sin3A binding at the p14ARF promoter (P < 0.05). These data support a model in which EBNA3C binds strongly to BATF/IRF4/SPI1/RUNX3 sites to enhance transcription and recruits RBPJ/Sin3A- and REST/NRSF-repressive complexes to repress p14ARF and p16INK4A expression.